Publications by authors named "Hazal Ozlen"
Background: Mindfulness, defined as nonjudgmental awareness of the present moment, has been associated with an array of mental and physical health benefits. Mindfulness may also represent a protective factor for Alzheimer's disease (AD). Here, we tested the potential protective effect of trait mindfulness on cognitive decline and AD pathology in older adults at risk for AD dementia.
View Article and Find Full Text PDFImportance: Preventive trials of anti-amyloid agents might preferably recruit persons showing earliest biologically relevant β-amyloid (Aβ) binding on positron emission tomography (PET).
Objective: To investigate the timing at which Aβ-PET binding starts showing associations with other markers of Alzheimer disease.
Design, Setting, And Participants: This longitudinal multicentric cohort study included 3 independent cohorts: Presymptomatic Evaluation of Experimental or Novel Treatments for Alzheimer Disease (PREVENT-AD) (data collected from 2012-2020), Alzheimer Disease Neuroimaging Initiative (ADNI) (data collected from 2005-2019), and Harvard Aging Brain Study (HABS) (data collected from 2011-2019).
Association of Elevated Amyloid and Tau Positron Emission Tomography Signal With Near-Term Development of Alzheimer Disease Symptoms in Older Adults Without Cognitive Impairment.
JAMA Neurol
October 2022
Importance: National Institute on Aging-Alzheimer's Association (NIA-AA) workgroups have proposed biological research criteria intended to identify individuals with preclinical Alzheimer disease (AD).
Objective: To assess the clinical value of these biological criteria to identify older individuals without cognitive impairment who are at near-term risk of developing symptomatic AD.
Design, Setting, And Participants: This longitudinal cohort study used data from 4 independent population-based cohorts (PREVENT-AD, HABS, AIBL, and Knight ADRC) collected between 2003 and 2021.
Objective: The objective of this study was to evaluate novel plasma p-tau231 and p-tau181, as well as Aβ and Aβ assays as indicators of tau and Aβ pathologies measured with positron emission tomography (PET), and their association with cognitive change, in cognitively unimpaired older adults.
Methods: In a cohort of 244 older adults at risk of Alzheimer's disease (AD) owing to a family history of AD dementia, we measured single molecule array (Simoa)-based plasma tau biomarkers (p-tau231 and p-tau181), Aβ and Aβ with immunoprecipitation mass spectrometry, and Simoa neurofilament light (NfL). A subset of 129 participants underwent amyloid-β ( F-NAV4694) and tau ( F-flortaucipir) PET assessments.
Article Synopsis
- The study aimed to explore how flortaucipir (FTP) levels relate to age and Alzheimer's disease indicators in asymptomatic adults at higher risk for the condition.
- Results indicated that older age correlated with higher FTP retention in certain brain areas and that individuals with positive β-amyloid (Aβ) markers exhibited elevated FTP levels, which tied into cognitive performance and cerebrospinal fluid (CSF) tau levels.
- The research suggests that low FTP-PET standardized uptake value ratios are linked to early Alzheimer's markers, emphasizing the need for tailored tau threshold adjustments based on different diagnostic purposes.